This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. For additional information, please visit Forward-looking Statements Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. The anti-mitotic program is evaluating CYC140, a PLK1 inhibitor, in advanced cancers. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, in solid tumors and hematological malignancies. He received his medical degree from the University of Pretoria, South Africa, completed a fellowship at the University of Toronto, Canada and practiced medicine prior to his career in the biopharmaceutical industry.Ĭyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. In addition, he serves as an advisor, SAB member and independent consultant for numerous biotech and investment companies. He is currently a Board Member of LifeSci Acquisition Corp, Mereo Biopharma and Enlivex. Schwartz was CMO at Ziopharm, having previously held several senior leadership roles at Bayer and LEO Pharma. During the past decade he has served as Senior Vice President, Head of Research & Development and Chief Medical Officer of ArQule Inc., which was acquired for $2.7bn by Merck & Co. Schwartz has wide-ranging experience as a drug development expert in pharmaceutical and biotechnology industries primarily in oncology, hematology, and rare diseases. The clinical development plans and Cyclacel’s experienced management team provide a strong basis for success in the Company’s programs.”ĭr. These two internally discovered molecules have competitive product profiles and address oncology indications with large unmet medical needs. “After evaluating the scientific and clinical merits of Cyclacel’s medicines, I am enthusiastic of the prospects of fadraciclib and CYC140. “I am excited to join the Board at an important moment in the Company’s history,” said Dr. “Brian’s experience in all development stages of innovative medicines for cancer will be very valuable as we advance our business strategy." His extensive clinical and product development experience further adds to the strength of our Board and will support management’s efforts to build shareholder value," said Christopher Henney, Ph.D., Chairman of the Board of Cyclacel. "We are very pleased to have Brian join the Board of Directors of Cyclacel. (NASDAQ: CYCC, NASDAQ: CYCCP "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the election of Brian Schwartz, M.D., to its Board of Directors. 21, 2020 (GLOBE NEWSWIRE) - Cyclacel Pharmaceuticals, Inc. Schwartz qualified as a medical doctor in South Africa followed by additional fellowship training in Canada.Former CMO & Head of R&D of ArQule joins the BoardīERKELEY HEIGHTS, N.J., Dec. Schwartz is a board member of Mereo Biopharma, Enlivex and Cyclacel pharmaceuticals and an advisor in different capacities to numerous biotech companies. Currently, in addition to the Infinity Board of Directors, Dr. Schwartz acquired knowledge of investors relations, partnering and capital raising. Schwartz has accumulated a number of successful new drug applications (NDAs), numerous investigational new drug (IND) applications, preclinical and clinical drug development programs. In senior leadership roles at ArQule, Ziopharm Oncology, Inc., Bayer AG, and LeoLabs, Inc., Dr. He was previously at ArQule for 10 years where he served as CMO prior to the acquisition by Merck & Co. Schwartz has over 25 years of experience as a drug development expert in pharmaceutical and biotechnology industries and has served as Infinity’s consulting Chief Physician since early 2020.
0 Comments
Leave a Reply. |